• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Minireview: Not picking pockets: nuclear receptor alternate-site modulators (NRAMs).小型综述:不掏兜:核受体别构调节剂(NRAMs)
Mol Endocrinol. 2010 Apr;24(4):683-95. doi: 10.1210/me.2009-0362. Epub 2009 Nov 20.
2
Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): multiple motifs with different binding specificities.共激活因子糖皮质激素受体相互作用蛋白1(GRIP1)和类固醇受体共激活因子1(SRC-1)的核受体结合位点:具有不同结合特异性的多个基序
Mol Endocrinol. 1998 Feb;12(2):302-13. doi: 10.1210/mend.12.2.0065.
3
A conserved surface on the ligand binding domain of nuclear receptors for allosteric control.核受体配体结合域上的变构调控的保守表面。
Mol Cell Endocrinol. 2012 Jan 30;348(2):394-402. doi: 10.1016/j.mce.2011.08.012. Epub 2011 Aug 22.
4
Conformational adaptation of nuclear receptor ligand binding domains to agonists: potential for novel approaches to ligand design.核受体配体结合域对激动剂的构象适应性:新型配体设计方法的潜力
J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):127-37. doi: 10.1016/j.jsbmb.2005.01.004. Epub 2005 Feb 19.
5
Mechanisms and significance of nuclear receptor auto- and cross-regulation.核受体自身和相互调控的机制及意义。
Gen Comp Endocrinol. 2011 Jan 1;170(1):3-17. doi: 10.1016/j.ygcen.2010.03.013. Epub 2010 Mar 23.
6
Steroid receptor/coactivator binding inhibitors: An update.甾体激素受体/共激活因子结合抑制剂:最新进展。
Mol Cell Endocrinol. 2019 Aug 1;493:110471. doi: 10.1016/j.mce.2019.110471. Epub 2019 Jun 1.
7
Nuclear receptor drug discovery.核受体药物研发
Curr Opin Chem Biol. 2008 Aug;12(4):418-26. doi: 10.1016/j.cbpa.2008.07.001. Epub 2008 Jul 26.
8
Interaction between the androgen receptor and a segment of its corepressor SHP.雄激素受体与其共抑制因子SHP的一段之间的相互作用。
Acta Crystallogr D Biol Crystallogr. 2007 Nov;63(Pt 11):1198-200. doi: 10.1107/S0907444907045702. Epub 2007 Oct 17.
9
Compound profiling using a panel of steroid hormone receptor cell-based assays.使用一组基于类固醇激素受体细胞的检测方法进行化合物分析。
J Biomol Screen. 2008 Sep;13(8):755-65. doi: 10.1177/1087057108322155. Epub 2008 Aug 27.
10
Allosteric small molecule modulators of nuclear receptors.核受体的变构小分子调节剂。
Mol Cell Endocrinol. 2019 Apr 5;485:20-34. doi: 10.1016/j.mce.2019.01.022. Epub 2019 Jan 28.

引用本文的文献

1
Mutational landscapes of HNF MODY gene products display a wide distribution with functional implications.肝细胞核因子(HNF)-成人发病型糖尿病(MODY)基因产物的突变图谱显示出广泛分布并具有功能意义。
Endocr Connect. 2025 Sep 2;14(9). doi: 10.1530/EC-25-0345. Print 2025 Sep 1.
2
Nuclear Receptors and the Hidden Language of the Metabolome.核受体与代谢组学的“隐语”
Cells. 2024 Jul 31;13(15):1284. doi: 10.3390/cells13151284.
3
Recent applications of computational methods to allosteric drug discovery.计算方法在变构药物发现中的最新应用。
Front Mol Biosci. 2023 Jan 12;9:1070328. doi: 10.3389/fmolb.2022.1070328. eCollection 2022.
4
Allosteric Antagonism of the Pregnane X Receptor (PXR): Current-State-of-the-Art and Prediction of Novel Allosteric Sites.变构拮抗剂的妊娠相关蛋白 X 受体(PXR):当前的最新研究进展和新变构结合位点的预测。
Cells. 2022 Sep 24;11(19):2974. doi: 10.3390/cells11192974.
5
A novel chemo-phenotypic method identifies mixtures of salpn, vitamin D3, and pesticides involved in the development of colorectal and pancreatic cancer.一种新型的化学表型方法鉴定了与结直肠癌和胰腺癌发展有关的唾液酸、维生素 D3 和农药的混合物。
Ecotoxicol Environ Saf. 2022 Mar 15;233:113330. doi: 10.1016/j.ecoenv.2022.113330. Epub 2022 Feb 19.
6
ER/AR Multi-Conformational Docking Server: A Tool for Discovering and Studying Estrogen and Androgen Receptor Modulators.雌激素受体/雄激素受体多构象对接服务器:一种用于发现和研究雌激素和雄激素受体调节剂的工具。
Front Pharmacol. 2022 Jan 24;13:800885. doi: 10.3389/fphar.2022.800885. eCollection 2022.
7
Structure-Activity Relationship Studies of Trisubstituted Isoxazoles as Selective Allosteric Ligands for the Retinoic-Acid-Receptor-Related Orphan Receptor γt.三取代异恶唑作为维 A 酸受体相关孤儿受体 γt 的选择性别构配体的构效关系研究。
J Med Chem. 2021 Jul 8;64(13):9238-9258. doi: 10.1021/acs.jmedchem.1c00475. Epub 2021 May 19.
8
Orthosteric and Allosteric Dual Targeting of the Nuclear Receptor RORγt with a Bitopic Ligand.核受体 RORγt 的双位点正构和变构双重靶向配体。
ACS Chem Biol. 2021 Mar 19;16(3):510-519. doi: 10.1021/acschembio.0c00941. Epub 2021 Feb 17.
9
LXRα Regulates ChREBPα Transactivity in a Target Gene-Specific Manner through an Agonist-Modulated LBD-LID Interaction.LXRα 通过激动剂调节的 LBD-LID 相互作用以靶基因特异性方式调节 ChREBPα 的转录活性。
Cells. 2020 May 13;9(5):1214. doi: 10.3390/cells9051214.
10
Nuclear receptor crosstalk - defining the mechanisms for therapeutic innovation.核受体相互作用——确定治疗创新的机制
Nat Rev Endocrinol. 2020 Jul;16(7):363-377. doi: 10.1038/s41574-020-0349-5. Epub 2020 Apr 17.

本文引用的文献

1
Novel flufenamic acid analogues as inhibitors of androgen receptor mediated transcription.新型氟灭酸类似物作为雄激素受体介导转录的抑制剂。
ACS Chem Biol. 2009 Oct 16;4(10):834-43. doi: 10.1021/cb900143a.
2
Perturbation of estrogen receptor alpha localization with synthetic nona-arginine LXXLL-peptide coactivator binding inhibitors.用合成的九聚精氨酸LXXLL-肽共激活剂结合抑制剂干扰雌激素受体α的定位
Chem Biol. 2009 Jul 31;16(7):702-11. doi: 10.1016/j.chembiol.2009.06.009.
3
Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists.第二位点雄激素受体拮抗剂对前列腺癌细胞生长的抑制作用
Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12178-83. doi: 10.1073/pnas.0900185106. Epub 2009 Jul 2.
4
Zebrafish development and regeneration: new tools for biomedical research.斑马鱼的发育与再生:生物医学研究的新工具
Int J Dev Biol. 2009;53(5-6):835-50. doi: 10.1387/ijdb.082615sb.
5
Understanding resistance to tamoxifen in hormone receptor-positive breast cancer.了解激素受体阳性乳腺癌对他莫昔芬的耐药性。
Clin Chem. 2009 Aug;55(8):1453-5. doi: 10.1373/clinchem.2009.125377. Epub 2009 Jun 18.
6
Image analysis in high-content screening.高内涵筛选中的图像分析
Comb Chem High Throughput Screen. 2009 Nov;12(9):899-907. doi: 10.2174/138620709789383213.
7
Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors.不可逆甲状腺受体共激活因子结合抑制剂药理性质的改善
J Med Chem. 2009 Jul 9;52(13):3892-901. doi: 10.1021/jm9002704.
8
Alternative inhibition of androgen receptor signaling: peptidomimetic pyrimidines as direct androgen receptor/coactivator disruptors.雄激素受体信号传导的替代抑制:拟肽嘧啶作为直接的雄激素受体/共激活因子破坏剂
ACS Chem Biol. 2009 Jun 19;4(6):435-40. doi: 10.1021/cb900043e.
9
Elucidating the 'Jekyll and Hyde' nature of PXR: the case for discovering antagonists or allosteric antagonists.阐明孕烷X受体的“双重性格”:发现拮抗剂或变构拮抗剂的理由。
Pharm Res. 2009 Aug;26(8):1807-15. doi: 10.1007/s11095-009-9901-7. Epub 2009 May 5.
10
Cyclic pyrrole-imidazole polyamides targeted to the androgen response element.靶向雄激素反应元件的环状吡咯-咪唑聚酰胺
J Am Chem Soc. 2009 May 27;131(20):7182-8. doi: 10.1021/ja901309z.

小型综述:不掏兜:核受体别构调节剂(NRAMs)

Minireview: Not picking pockets: nuclear receptor alternate-site modulators (NRAMs).

作者信息

Moore Terry W, Mayne Christopher G, Katzenellenbogen John A

机构信息

Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA.

出版信息

Mol Endocrinol. 2010 Apr;24(4):683-95. doi: 10.1210/me.2009-0362. Epub 2009 Nov 20.

DOI:10.1210/me.2009-0362
PMID:19933380
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2852352/
Abstract

Because of their central importance in gene regulation and mediating the actions of many hormones, the nuclear receptors (NRs) have long been recognized as very important biological and pharmaceutical targets. Of all the surfaces available on a given NR, the singular site for regulation of receptor activity has almost invariably been the ligand-binding pocket of the receptor, the site where agonists, antagonists, and selective NR modulators interact. With our increasing understanding of the multiple molecular components involved in NR action, researchers have recently begun to look to additional interaction sites on NRs for regulating their activities by novel mechanisms. The alternate NR-associated interaction sites that have been targeted include the coactivator-binding groove and allosteric sites in the ligand-binding domain, the zinc fingers of the DNA-binding domain, and the NR response element in DNA. The studies thus far have been performed with the estrogen receptors, the androgen receptor (AR), the thyroid hormone receptors, and the pregnane X receptor. Phenotypic and conformation-based screens have also identified small molecule modulators that are believed to function through the NRs but have, as yet, unknown sites and mechanisms of action. The rewards from investigation of these NR alternate-site modulators should be the discovery of new therapeutic approaches and novel agents for regulating the activities of these important NR proteins.

摘要

由于核受体(NRs)在基因调控以及介导多种激素作用方面具有核心重要性,长期以来它们一直被视为非常重要的生物学和药物靶点。在给定的核受体上所有可利用的表面中,几乎无一例外,调节受体活性的唯一部位一直是受体的配体结合口袋,即激动剂、拮抗剂和选择性核受体调节剂相互作用的部位。随着我们对参与核受体作用的多种分子成分的了解不断增加,研究人员最近开始寻找核受体上的其他相互作用位点,以通过新机制调节其活性。已被靶向的其他与核受体相关的相互作用位点包括配体结合域中的共激活因子结合凹槽和别构位点、DNA结合域的锌指以及DNA中的核受体反应元件。迄今为止,这些研究是针对雌激素受体、雄激素受体(AR)、甲状腺激素受体和孕烷X受体进行的。基于表型和构象的筛选也鉴定出了一些小分子调节剂,据信它们通过核受体发挥作用,但作用位点和作用机制尚不清楚。研究这些核受体替代位点调节剂有望发现新的治疗方法和新型药物,用于调节这些重要核受体蛋白的活性。